Table 1.
Baseline characteristics
| Characteristic | NIAT-Rituximab Group, n=37 | NIAT Group, n=38 | Total, n=75 |
|---|---|---|---|
| Age, yr | 53.0 (42.0–63.0) | 58.5 (43.0–64.0) | 56 (42.0–64.0) |
| Men, no. (%) | 28 (75.7) | 24 (63.2) | 52 (69.3) |
| Weight, kg | 76.0 (70.0–85.0) | 76.5 (67.0–85.0) | 76.0 (67.0–85.0) |
| BP, mmHg | |||
| Systolic | 124 (110–140) | 125 (117–140) | 125 (115–140) |
| Diastolic | 77 (68–82) | 76 (70–81) | 76 (70–81) |
| Creatinine, μmol/L | 98.1 (73.4–122.9) | 91.1 (74.3–122.0) | 93.8 (76.9–122.9) |
| eGFR, ml/min per 1.73 m2 | 66.7 (55.4–82.5) | 72.7 (58.1–88.6) | 68.6 (55.4–88.6) |
| Protein-to-creatinine ratio, mg/g | 7680.0 (4584.3–10,399.0) | 7195.1 (5363.1–8965.1) | 7363.2 (4702.9–9735.0) |
| Albumin level, g/L | 22 (18–25) | 22 (20–26) | 22 (19–26) |
| Median time since biopsy-proven diagnosis, mo | 8 (6–13) | 8 (6–11) | 8 (6–13) |
| PLA2R-Ab–positive patients (ELISA), no. (%) | 27 (73.0) | 28 (73.7) | 55 (73.3) |
| PLA2R-Ab titer (ELISA), RU/mla | 40.5 (0.0–275.5) | 43.3 (0.0–457.5) | 40.5 (0.0–440.9) |
| Diuretics, no. (%) | 32 (86.5) | 32 (84.2) | 64 (85.3) |
| ACE inhibitor and/or ARB, no. (%) | |||
| ACE inhibitor | 16 (43.2) | 14 (38.9) | 30 (41.1) |
| ARB | 12 (32.4) | 8 (22.2) | 20 (27.4) |
| ACE inhibitor and ARB | 9 (24.3) | 14 (38.9) | 23 (31.51) |
| Statins, no. (%) | 31 (83.8) | 26 (68.4) | 57 (76.0) |
Data are shown as n (%) or median (IQR). eGFR was calculated according to the MDRD equation. ACE, angiotensin-converting enzyme; ARB, angiotensin 2 receptor blocker.
a
Median and IQR of PLA2R-Ab titer in all patients with and without PLA2R-Ab.